Etavopivat C — Competitive Intelligence Brief

Etavopivat C (Etavopivat C) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pyruvate dehydrogenase kinase inhibitor. Area: Hematology/Rare Blood Disorders.

phase 3 Pyruvate dehydrogenase kinase inhibitor PDK (pyruvate dehydrogenase kinase) Hematology/Rare Blood Disorders Small molecule

Target snapshot

Etavopivat C (Etavopivat C) — Novo Nordisk A/S. Etavopivat activates the pyruvate dehydrogenase kinase (PDK) inhibitor pathway to reduce hemolysis in sickle cell disease by modulating red blood cell metabolism.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Etavopivat C TARGET	Etavopivat C	Novo Nordisk A/S	phase 3	Pyruvate dehydrogenase kinase inhibitor	PDK (pyruvate dehydrogenase kinase)
Etavopivat B	Etavopivat B	Novo Nordisk A/S	phase 3	Pyruvate dehydrogenase kinase inhibitor	PDK (Pyruvate dehydrogenase kinase)
Dichloroacetate (DCA)	Dichloroacetate (DCA)	University of Florida	phase 3	Pyruvate dehydrogenase kinase inhibitor	Pyruvate dehydrogenase kinase (PDK)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pyruvate dehydrogenase kinase inhibitor class)

1. Novo Nordisk A/S · 2 drugs in this class
2. University of Florida · 1 drug in this class